MARKET

AEZS

AEZS

Aeterna Zentaris Inc
NASDAQ
2.190
+0.110
+5.29%
After Hours: 2.180 -0.01 -0.46% 18:44 03/28 EDT
OPEN
2.050
PREV CLOSE
2.080
HIGH
2.190
LOW
2.010
VOLUME
49.62K
TURNOVER
0
52 WEEK HIGH
3.380
52 WEEK LOW
1.360
MARKET CAP
10.63M
P/E (TTM)
-0.4551
1D
5D
1M
3M
1Y
5Y
Aeterna Zentaris Announces Merger Approval
TipRanks · 17h ago
Aeterna Zentaris Announces Merger with Ceapro Inc.
Aeterna Zentaris Inc. Is set to merge with Ceapro Inc. The all-stock merger is expected to be completed in the second quarter of 2024. The move is anticipated to enhance their offerings in pharmaceutical and diagnostic products. TSE:AEZS has received final court approval for the merger.
TipRanks · 20h ago
*AEterna Zentaris and Ceapro Anticipate Completing the Transaction in the 2Q of 2024 >AEZS
Dow Jones · 21h ago
*Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris AEZS
Dow Jones · 21h ago
AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023
AEterna Zentaris reported earnings per share of -$1.16. This was below the analyst estimate for EPS of -97 cents. The company reported revenue of $121,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 1d ago
Aeterna Zentaris Financials Affirm Compliance
TipRanks · 1d ago
Aeterna Zentaris Completes Key Trial Enrollment
TipRanks · 1d ago
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
More
About AEZS
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Webull offers AEterna Zentaris Inc. (USA) stock information, including NASDAQ: AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.